Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Samsung Biologics set a new earnings record last year, surpassing 5 trillion won ($3.59 billion) in cumulative orders for 2024 for the first time in the company’s history. Given the significance ...

Medical-device maker Stryker on Monday agreed to acquire Inari Medical , which makes devices that treat patients with venous diseases, in an all-cash deal worth $4.9 billion.

The spokesperson explained that having a history in the country means that ... to buy a vaccines manufacturing facility from WuXi Biologics in Dundalk. Join the conversation, on Tuesday 28th ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new ...

Its sister company WuXi Biologics rose 4.7%, while WuXi XDC, a contract medical research unit of WuXi Biologics, was up 5.0%. The WuXi companies have come under scrutiny amid tensions between the ...